Page last updated: 2024-09-05

sorafenib and ponatinib

sorafenib has been researched along with ponatinib in 21 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(ponatinib)
Trials
(ponatinib)
Recent Studies (post-2010) (ponatinib)
6,5207305,25153834519

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)ponatinib (IC50)
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)0.0038
Tyrosine-protein kinase JAK2Homo sapiens (human)0.169
Tyrosine-protein kinase ABL1Homo sapiens (human)0.0037
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)0.0009
High affinity nerve growth factor receptorHomo sapiens (human)0.0114
Tyrosine-protein kinase LckHomo sapiens (human)0.0003
Tyrosine-protein kinase FynHomo sapiens (human)0.0004
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0086
Tyrosine-protein kinase YesHomo sapiens (human)0.0009
Tyrosine-protein kinase LynHomo sapiens (human)0.0008
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.0357
Hepatocyte growth factor receptorHomo sapiens (human)0.0017
Tyrosine-protein kinase HCKHomo sapiens (human)0.0001
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0012
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0271
Breakpoint cluster region proteinHomo sapiens (human)0.0008
Fibroblast growth factor receptor 1Homo sapiens (human)0.0016
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.0053
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.0016
cAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)0.613
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.0123
Ephrin type-A receptor 1Homo sapiens (human)0.143
Fibroblast growth factor receptor 2Homo sapiens (human)0.0018
Fibroblast growth factor receptor 4Homo sapiens (human)0.0058
Fibroblast growth factor receptor 3Homo sapiens (human)0.0099
Tyrosine-protein kinase JAK1Homo sapiens (human)0.0322
Ephrin type-A receptor 2Homo sapiens (human)0.0013
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0053
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0086
Tyrosine-protein kinase CSKHomo sapiens (human)0.0127
Tyrosine-protein kinase FRKHomo sapiens (human)0.0013
Glycogen synthase kinase-3 betaHomo sapiens (human)2.8
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)0.0094
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)4.385
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)0.012
Coiled-coil domain-containing protein 6Homo sapiens (human)0.1804
Mitogen-activated protein kinase 14Homo sapiens (human)0.01
Leucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)0.48
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.04
Receptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)0.0016

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's14 (66.67)24.3611
2020's7 (33.33)2.80

Authors

AuthorsStudies
Beck, ME; Braun, CA; Getlik, M; Grütter, C; Gutbrod, O; Mayer-Wrangowski, SC; Pérez-Martín, J; Rauh, D; Richters, A; Schreier, PH; Simard, JR1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Song, M1
Adeniji-Popoola, O; Blagg, J; Blaukat, A; Box, G; Clarke, PA; Court, W; Czodrowski, P; Dale, T; de Haven Brandon, A; Eccles, SA; Esdar, C; Ewan, K; Fraser, E; Gowan, S; Mallinger, A; Musil, D; Ortiz-Ruiz, MJ; Poeschke, O; Raynaud, F; Rohdich, F; Samant, RS; Schiemann, K; Schneider, K; Schneider, R; Schwarz, D; Stubbs, M; TePoele, R; Valenti, M; Waalboer, D; Wienke, D; Workman, P1
Bestgen, B; Borjini, N; Chevé, G; Daydé-Cazals, B; Fauvel, B; Feneyrolles, C; Gassiot, F; Singer, M; Spenlinhauer, A; Van Hijfte, N; Warnault, P; Yasri, A1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Al-Ansary, GH; Al-Rashood, ST; Ali, MM; El Kerdawy, AM; Eldehna, WM; Mahmoud, AE1
Chen, F; Zhuang, C1
He, G; Jin, Y; Li, K; Lin, J; Liu, F; Xie, M; Yu, W; Zhang, C; Zhang, J; Zhao, Y; Zhu, C1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A1
Acharya, B; Frett, B; Garcia, NG; Lakkaniga, NR; Ryan, KR; Saha, D; Smith, EL1
Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Shi, K; Wang, J; Wang, Y; Zhang, J; Zhou, E1
Damon, LE; Lasater, EA; Lin, KC; Salerno, S; Shah, NP; Smith, CC; Stewart, WK; Zhu, X1
Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F1
Fleischmann, M; Hilgendorf, I; Hochhaus, A; Sayer, HG; Schmidt, V; Schnetzke, U; Scholl, S; Schrenk, KG1
Bonsignore, R; Gentile, C; Lauria, A; Martorana, A1
Abegg, VF; Bouitbir, J; Grünig, D; Krähenbühl, S; Mingard, C; Paech, F1
Fulda, S1
Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM1

Reviews

9 review(s) available for sorafenib and ponatinib

ArticleYear
Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.
    Journal of medicinal chemistry, 2020, 02-27, Volume: 63, Issue:4

    Topics: Animals; Cell Line, Tumor; Drug Development; Humans; Molecular Structure; Necroptosis; Protein Kinase Inhibitors; Receptor-Interacting Protein Serine-Threonine Kinases

2020
Kinase Inhibitors as Underexplored Antiviral Agents.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses

2022
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
    Journal of medicinal chemistry, 2021, 08-26, Volume: 64, Issue:16

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Development; Humans; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret

2021
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022
Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.
    Journal of medicinal chemistry, 2022, 11-24, Volume: 65, Issue:22

    Topics: Apoptosis; Chemistry, Pharmaceutical; Drug Discovery; Humans; Receptor-Interacting Protein Serine-Threonine Kinases

2022
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:7

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine

2014
Kinase Inhibitors in Multitargeted Cancer Therapy.
    Current medicinal chemistry, 2017, Volume: 24, Issue:16

    Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib

2017
Repurposing anticancer drugs for targeting necroptosis.
    Cell cycle (Georgetown, Tex.), 2018, Volume: 17, Issue:7

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Drug Repositioning; Humans; Imidazoles; Indazoles; Necrosis; Oximes; Pyridazines; Pyrimidines; Reperfusion Injury; Sorafenib; Sulfonamides; Systemic Inflammatory Response Syndrome; Vemurafenib

2018
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Minerva medica, 2020, Volume: 111, Issue:5

    Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine

2020

Other Studies

12 other study(ies) available for sorafenib and ponatinib

ArticleYear
Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals.
    ACS chemical biology, 2012, Jul-20, Volume: 7, Issue:7

    Topics: Amino Acid Sequence; Antifungal Agents; Crystallography, X-Ray; Drug Delivery Systems; Glycogen Synthase Kinase 3; Humans; Molecular Sequence Data; Protein Kinase Inhibitors; Ustilago

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
    Journal of medicinal chemistry, 2015, May-14, Volume: 58, Issue:9

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Kinesins; Lung Neoplasms; Models, Molecular; Protein Conformation

2015
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
    Nature chemical biology, 2015, Volume: 11, Issue:12

    Topics: Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinase 8; Cyclin-Dependent Kinases; Humans; Models, Molecular; Molecular Probes; Molecular Structure; Protein Kinase Inhibitors; Pyridines; Spiro Compounds

2015
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
    Journal of medicinal chemistry, 2016, 04-28, Volume: 59, Issue:8

    Topics: Animals; Cell Proliferation; Drug Design; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Male; Mice; Patch-Clamp Techniques; Protein Kinase Inhibitors

2016
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel ind
    European journal of medicinal chemistry, 2019, Feb-01, Volume: 163

    Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Indoles; Models, Molecular; Oxindoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Structure-Activity Relationship; Sunitinib; TYK2 Kinase; Vascular Endothelial Growth Factor Receptor-2

2019
Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking.
    Bioorganic & medicinal chemistry letters, 2019, 12-01, Volume: 29, Issue:23

    Topics: Aniline Compounds; Humans; Molecular Docking Simulation; Quinazolines; Vascular Endothelial Growth Factor Receptor-2

2019
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
    Bioorganic & medicinal chemistry, 2022, 02-15, Volume: 56

    Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship

2022
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Blood, 2013, Apr-18, Volume: 121, Issue:16

    Topics: Amino Acid Sequence; Amino Acid Substitution; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridazines; Quinolines; Sorafenib

2013
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridazines; Retrospective Studies; Sorafenib; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult

2017
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
    Toxicology, 2018, 02-15, Volume: 395

    Topics: Adenosine Triphosphate; Animals; Apoptosis; Cytochromes c; Electron Transport; Hep G2 Cells; Humans; Imidazoles; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Mitophagy; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridazines; Pyridines; Sorafenib

2018